A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Li, Xin Ping ^a   Jing, Wei ^a   Sun, Jian Jun ^a   Liu, Zhong Yan ^a   Zhang, Jing Tao ^a   Sun, Wei ^a   Zhu, Wei ^a   Fan, Yue Zu ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antilymphangiogenic therapy; Colonic neoplasm; Lymphangiogenesis; Norcantharidin; Tumor growth

Indexed keywords

CYTOKERATIN 20; KI 67 ANTIGEN; LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR 1; MONOCLONAL ANTIBODY D2-40; NORCANTHARIDIN; PROTEIN BCL 2; SORAFENIB; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL FUNCTIONS; CANCER INHIBITION; COLON ADENOCARCINOMA; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN COLONIC ADENOCARCINOMA; IN VITRO STUDY; IN VIVO STUDY; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MALE; METASTASIS; MOUSE; MULTIPOINTS PRIMING; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COLONIC NEOPLASMS; CYTOLOGY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; HT-29 CELL LINE; LYMPHATIC METASTASIS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; IN VITRO TECHNIQUES; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MICE; MICE, NUDE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937580152     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1521-5     Document Type: Article

References (64)

1. An WW, Wang MW, Tashiro SI, Onodera S, Ikejima T. Mitogen-activated protein kinase-dependent apoptosis in norcantharidin-treated A357-S2 cells is proceeded by the activation of protein kinase C. Chin Med J. 2005;118:198-203.
2. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154:385-94.
3. Chen YN, Chen JC, Yin SC, Wang GS, Tsauer W, Hsu SF, Hsu SL. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer. 2002;100:158-65.
4. Chen YJ, Tsai YM, Kuo CD, Ku KL, Shie HS, Liao HF. Norcantharidin is a small-molecule synthetic compound with anti-angiogenesis effect. Life Sci. 2009;85:642-51.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of Sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
6. Dong Z, Wei F, Zhou C, Sumida T, Hamakawa H, Hu Y, Liu S Silencing Id-1 inhibits lymphangiogenesis through down-regulation of VEGF-C in oral squamous cell carcinoma. Oral Oncol. 2011;47:27-32.
7. Dong X, Zhao X, Xiao T, Tian H, Yun C. Endostar, a recombined humanized endostatin, inhibits lymphangiogenesis and lymphatic metastasis of lewis lung carcinoma xenograft in mice. Thorac Cardiovasc Surg. 2011;59:133-6.
8. Fan YZ, Fu JY, Zhao ZM, Chen CQ. Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells. World J Gastroenterol. 2005;11:2431-7.
9. Fan YZ, Fu JY, Zhao ZM, Chen CQ. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. Hepatobil Pancreat Dis Int. 2007;6:72-80.
10. Fan YZ, Li GM, Huang GP, Li XP. Clinical significance of detection on lymphatic microvessel, lymphatic microvessel density and vascular endothelial growth factor-C in patients with colorectal carcinoma. Zhonghua Wei Chang Wai Ke Za Zhi. 2006;9:477-82.
11. Fan YZ, Li GM, Huang GP, Li XP. Expression of vascular endothelial growth factor-C, -D and their receptor-3 (VEGFR-3) in patients with colorectal cancer and their clinicopathological value. Zhonghua Xiao Hua Za Zhi. 2006;26:739-43.
12. Fan YZ, Zhao ZM, Fu JY, Chen CQ, Sun W. Norcantharidin inhibits growth of human gallbladder carcinoma xenograft tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo. Hepatobil Pancreat Dis Int. 2010;9:414-22.
13. Fogt F, Zimmerman RL, Ross HM, Daly T, Gausas RE. Identification of lymphatic vessels in malignant, adenomatous and normal colonic mucosa using the novel immunostain D2-40. Oncol Rep. 2004;11:47-50.
14. Guo B, Zhang Y, Luo G, Li L, Zhang J. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma. Anat Rec (Hoboken). 2009;292:633-9.
15. Ho YP, To KK, Au-Yeung SC, Wang X, Lin G, Han X. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J Med Chem. 2001;44:2065-8.
16. Hu J, Ye H, Fu A, Chen X, Wang Y, Chen X, Ye X, Xiao W, Duan X, Wei Y, Chen L. Deguelin-an inhibitor to tumor lymphangiogenesis lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model. Int J Cancer. 2010;127:2455-66.
17. Jackson DG. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS. 2004;112:526-38.
18. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research. PLoS Biol. 2010;8(6):e1000412.
19. Kok SH, Cheng SJ, Hong CY, Lee JJ, Lin SK, Kuo YS, Chiang CP, Kuo MY. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett. 2005;217:43-52.
20. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12:5018-22.
21. Li JL, Cai YC, Liu XH, Xian LJ. Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage of initiation protein Cdc6 in HL-60 cells. Anticancer Drugs. 2006;17:307-14.
22. Li ZX, Zhang GF, Hu ZQ, Fan YZ. Expression of lymphatic vessel endothelial hyaluronan receptor-1 in human colorectal cancer and its clinical significance. Zhonghua Wei Chang Wai Ke Za Zhi. 2009;12:511-4.
23. Liu ZY, Qiu HO, Yuan XJ, Ni YY, Sun JJ, Jing W, Fan YZ. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and -D/VEGFR-3 with norcantharidin. Int J Oncol. 2012;41:1762-72.
24. Liu H, Yang Y, Xiao J, LV Y, Liu Y, Yang H, Zhao L. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C. Anat Rec (Hoboken). 2009;292:1577-83.
25. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009;21:154-65.
26. Lui Z, Ma Q, Wang X, Zhang Y. Inhibiting tumor growth of colorectal cancer by blocking the expression of vascular endothelial growth factor receptor 3 using interference vector-based RNA interference. Int J Mol Med. 2010;25:59-64.
27. Luo Y, Liu L, Rogers D, Su W, Odaka Y, Zhou H, Chen W, Shen T, Alexander JS, Huang S. Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression. Neoplasia 2012;14:228-37.
28. McColl BK, Loughran SJ, Davydova N, Stacker SA, Achen MG. Mechanisms of lymphangiogenesis: targets for blocking the metastatic spread of cancer. Curr Cancer Drug Targets. 2005;5:561-71.
29. Moll R, Zimbelmann R, Goldschmidt MD, Keith M, Laufer J, Kasper M, Koch PJ, Franke WW. The human gene encoding cytokeratin 20 and its expression during fetal development and in gastrointestinal carcinomas. Differentiation. 1993;53:75-93.
30. Moreno Garcia V, Basu B, Molife LR, Kaye SB. Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res. 2012;18:3750-61.
31. Nagahashi M, Ramachandran S, Rashid OM, Takabe K. Lymphangiogenesis: a new player in cancer progression. World J Gastroenterol. 2010;16:4003-12.
32. Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002;196:1497-506.
33. Okazaki H, Tokumaru S, Hanakawa Y, Shiraishi K, Shirakata Y, Dai X, Yang L, Tohyama M, Hashimoto K, Sayama K. Nuclear translocation of phosphorylated STAT3 regulates VEGF-A-induced lymphatic endothelial cell migration and tube formation. .Biochem Biophys Res Commun. 2011;412:441-5.
34. Peng F, Wei YQ, Tian L, Yang L, Zhao X, Lu Y, Mao YQ, Kan B, Lei S, Wang GS, Jiang Y, Wang QR, Luo F, Zou LQ, Liu JY. Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. J Cancer Res Clin Oncol. 2002;128:223-30.
35. Pytowski B, Goldman J, Persaud K, Wu Y, Witte L, Hicklin DJ, Skobe M, Boardman KC, Swartz MA. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst. 2005;97:14-21.
36. Qiu XF, Yao SJ, Zhang SQ. Advances in the research on lymphangiogenesis in carcinoma tissues. Oncol Lett. 2010;1:579-82.
37. Raica M, Ribatti D. Targeting tumor lymphangiogenesis: an update. Curr Med Chem. 2010;17:698-708.
38. Ranieri G, Gadaleta-Caldarola G, Goffredo V, Patruno R, Mangia A, Rizzo A, Sciorsci RL, Gadaleta CD. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr Med Chem. 2012;19:938-44.
39. Roskoski Jr R. VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun. 2008;375:287-91.
40. Saad RS, Kordunsky L, Liu YL, Denning KL, Kandil HA, Silverman JF. Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol. 2006;19:1317-23.
41. Scavelli C, Vacca A, Di Pietro G, Dammacco F, Ribatti D. Crosstalk between angiogenesis and lymphangiogenesis in tumor progression. Leukemia. 2004;18:1054-8.
42. Sieghart W, Pinter M, Reisegger M, Müller C, Ba-Ssalamah A, Lammer J, Peck-Radosavljevic M. Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellularcarcinoma: a pilot study. Eur Radiol. 2012;22:1214-23.
43. Sleeman JP, Thiele W. Tumor metastasis and the lymphatic vasculature. Int J Cancer. 2009;125:2747-56.
44. Spigel DR, Burris HA, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J,Bass JD, Hainsworth JD. Randomized, double-blind, placebo- controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non- small-cell lung cancer. J Clin Oncol. 2011;29:2582-9.
45. Strumberg D. Sorafenib for the treatment of renal cancer. Expert Opin Pharmacother. 2012;13:407-19.
46. Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, Chen HY, Hung MC, Kuo ML. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 2007;96:541-5.
47. Sun JJ, Jing W, Ni YY, Yuan XJ, Zhou HH, Fan YZ. New model of in-situ xenograft lymphangiogenesis by a human colonic adenocarcinoma cell line in nude mice. Asian Pac J Cancer Prev. 2012;13:2823-8.
48. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471-94.
49. Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol. 1989;26:147-62.
50. Wang J, Guo Y, Wang B, Bi J, Li K, Liang X, Chu H, Jiang H. Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature. Mol Biol Rep. 2012;39:11153-65.
51. Wang H, Sun W, Zhang WZ, Ge CY, Zhang JT, Liu ZY, Fan YZ. Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/Paxillin signaling pathway. PLoS One. 2014;9(5):e96882.
52. Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, Wang YS, Li J, Chen P, Tang MH, Shao XM, Lu Y, Zhao X, Wei YQ: Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int J Cancer 2009;124:2709-18.
53. Wijesuriya SR, Kuruppuarachchi KG, Weerasinghe A, Hewavisenthi J, Deen KI. Detection of micrometastases in lymph nodes using reverse transcription polymerase chain reaction (RT-PCR) for cytokeratin 20 (CK-20)--a pilot study. Ceylon Med J. 2010;55:77-9.
54. Wong CS, Cheung MT, Ma BB, Pun Hui E, Chan AC, Chan CK, Lee KC, Cheuk W, Lam MY, Wong MC, Chan CM, Chan JK, Chan AT. Isolated tumor cells and circulating CK20 mRNA in pN0 colorectal cancer patients. Int J Surg Pathol. 2008;16:119-26.
55. Wu LT, Chung JG, Chen JC, Tsauer W. Effect of norcantharidin on N-acetyltransferase activity in HepG2 cells. Am J Chin Med. 2001;29:161-72.
56. Yadav A, Kumar B, Teknos TN, Kumar P. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther. 2011;10:1241-51.
57. Yang XM, Han HX, Sui F, Dai YM, Chen M, Geng JG. Slit-Robo signaling mediates lymphangiogenesis and promotes tumor lymphatic metastasis. Biochem Biophys Res Commun. 2010;396:571-7.
58. Yang EB, Tang WY, Zhang K, Cheng LY, Mack PO. Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett. 1997;117:93-8.
59. Yi SN, Wass J, Vincent P, Iland H. Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk Res. 1991;15:883-6.
60. Yu CC, Ko FY, Yu CS, Lin CC, Huang YP, Yang JS, Lin JP, Chung JG. Norcantharidin triggers cell death and DNA damage through S-phase arrest and ROS-modulated apoptotic pathways in TSGH 8301 human urinary bladder carcinoma cells. Int J Oncol. 2012;41:1050-60.
61. Zhang JT, Fan YZ, Chen CQ, Zhao ZM, Sun W. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo. Int J Oncol. 2012;40:1501-14.
62. Zhang L, Ji Q, Liu X, Chen X, Chen Z, Qiu Y, Sun J, Cai J, Zhu H, Li Q. Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways. Cancer Sci. 2013;104:604-10.
63. 2 signaling pathway. BMC Cancer. 2014;14:193.
64. Zwaans BM, Bielenberg DR: Potential therapeutic strategies for lymphatic metastasis. Microvasc Res. 2007;74:145-58.